Nabriva Therapeutics Chooses TransPerfect Trial Interactive to Oversee Its Licensing Process

Published: Sep 27, 2011

NEW YORK--(BUSINESS WIRE)--TransPerfect Trial Interactive, a leading provider of product licensing and alliance management, eTMF, and pharmacovigilance solutions, announced today that Nabriva Therapeutics has implemented the Trial Interactive platform. Nabriva is using the platform to collaborate and share information with potential partners for the licensing of the first of a new class of antibiotics, BC-3781, which completed a phase II trial in 2011. BC-3781 is being developed for the treatment of serious multi-drug-resistant skin and skin-structure infections and bacterial pneumonia.

Back to news